Clinical relevance of antibiotic resistance in obstetrics and gynecology;Klinische bedeutung der antibiotikaresistenz in gynäkologie und geburtshilfe

Gynakologisch-geburtshilfliche Rundschau

Volumn 45, Issue 1, 2005, Pages 19-27

  Ruef, Christian ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibiotic resistance; Chlamydia trachomatis; Fluoroquinolones; Gardnerella vaginalis; Group B streptococci; Macrolides; Mycoplasma hominis; Trichomonas vaginalis

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GARENOXACIN; GLYCOPEPTIDE; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; METRONIDAZOLE; MOXIFLOXACIN; PAROMOMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULTAMICILLIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIUM ISOLATION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; GARDNERELLA VAGINALIS; GYNECOLOGIC INFECTION; HUMAN; METHODOLOGY; MYCOPLASMA HOMINIS; NONHUMAN; OBSTETRICS; PATHOGENESIS; REVIEW; STREPTOCOCCACEAE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UROGENITAL TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 12544249386     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081713     Document Type: Review

References (68)

1. Wisplinghoff H, Bischoff T, Tallent S, Seifert H, Wenzel R, Edmond M: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
2. Cates W Jr: Estimates of the incidence and prevalence of sexually transmitted diseases in the United States: American Social Health Association Panel. Sex Transm Dis 1999;26 (suppl):S2-7.
3. Soper D: Trichomoniasis: Under control or undercontrolled? Am J Obstet Gynecol 2004;190:281-290.
4. Sorvillo F, Smith L, Kerndt P, Ash L: Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001;7:927-932.
5. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51(RR-6):1-78.
6. Klebanoff MA, Carey JC, Hauth JC, et al: Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487-493.
7. Dunne RL, Dunn LA, Upcroft P, O'Donoghue PJ, Upcroft JA: Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003;13:239-249.
8. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H: Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001;46:545-549.
9. Lossick JG, Kent HL: Trichomoniasis: Trends in diagnosis and management. Am J Obstet Gynecol 1991;165:1217-1222.
10. Sobel JD, Nagappan V, Nyirjesy P: Metronidazole-resistant vaginal trichomoniasis - An emerging problem. N Engl J Med 1999;341:292-293.
11. Crowell AL, Sanders-Lewis KA, Secor WE: In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003;47:1407-1409.
12. Lossick JG, Muller M, Gorrell TE: In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986;153:948-955.
13. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS: Tinidazole: A review of its antiprotozoal activity and therapeutic efficacy. Drugs 1976;11:423-440.
14. Sobel JD, Nyirjesy P, Brown W: Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341-1346.
15. Hager WD: Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: Case reports of three patients. Sex Transm Dis 2004;31:343-345.
16. Meri T, Jokiranta TS, Suhonen L, Meri S: Resistance of Trichomonas vaginalis to metronidazole: Report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 2000;38:763-767.
17. Poppe WA: Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol 2001;96:119-120.
18. Camuzat-Dedenis B, Provot O, Cointeaux L, et al: Synthesis and in vitro trichomonacidal activities of some new dialkylperoxides and 1,2,4-trioxanes. Eur J Med Chem 2001;36:837-842.
19. Bouma MJ, Snowdon D, Fairlamb AH, Ackers JP: Activity of disulfiram [bis(diethylthiocarbamoyl)disulphide] and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. J Antimicrob Chemother 1998;42:817-820.
20. Kaul R, Kimani J, Nagelkerke NJ, et al: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: A randomized controlled trial. JAMA 2004;291:2555-2562.
21. Carey JC, Klebanoff MA: Bacterial vaginosis and other asymptomatic vaginal infections in pregnancy. Curr Womens Health Rep 2001;1:14-19.
22. Johnson AP, Boustouller YL: Extra-vaginal infection caused by Gardnerella vaginalis. Epidemiol Infect 1987;98:131-137.
23. Amaya RA, Al-Dossary F, Demmler GJ: Gardnerella vaginalis bacteremia in a premature neonate. J Perinatol 2002;22:585-587.
24. Kharsany AB, Hoosen AA, Van den Ende J: Antimicrobial susceptibilities of Gardnerella vaginalis. Antimicrob Agents Chemother 1993;37:2733-2735.
25. Pheifer TA, Forsyth PS, Durfee MA, Pollock HM, Holmes KK: Nonspecific vaginitis: Role of Haemophilus vaginalis and treatment with metronidazole. N Engl J Med 1978;298:1429-1434.
26. Goldstein EJ, Citron DM, Cherubin CE, Hillier SL: Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993;31:363-372.
27. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HAT: In vitro activities of garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother 2002;46:3995-3996.
28. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH: Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004;4:5.
29. Geissdorfer W, Bohmer C, Pelz K, Schoerner C, Frobenius W, Bogdan C: Tuboovarian abscess caused by Atopobium vaginae following transvaginal oocyte recovery. J Clin Microbiol 2003;41:2788-2790.
30. Manning S, Neighbors K, Tallman P, et al: Prevalence of group B streptococcus colonization and potential for transmission by casual contact in healthy young men and women. Clin Infect Dis 2004;39:380-388.
31. Thinkhamrop J, Limpongsanurak S, Festin MR, et al: Infections in international pregnancy study: Performance of the optical immunoassay test for detection of group B streptococcus. J Clin Microbiol 2003;41:5288-5290.
32. Weisner AM, Johnson AP, Lamagni TL, et al: Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 2004;38:1203-1208.
33. Heath PT, Balfour G, Weisner AM, et al: Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004;363:292-294.
34. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A: Prevention of perinatal group B streptococcal disease: Revised guidelines from CDC. MMWR Recomm Rep 2002;51(RR-11):1-22.
35. Schrag SJ, Schuchat A: Easing the burden: Characterizing the disease burden of neonatal group B streptococcal disease to motivate prevention. Clin Infect Dis 2004;38:1209-1211.
36. Biedenbach DJ, Stephen JM, Jones RN: Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program -North America, 2001. Diagn Microbiol Infect Dis 2003;46:291-294.
37. Arisoy AS, Altinisik B, Tunger O, Kurutepe S, Ispahi C: Maternal carriage and antimicrobial resistance profile of group B streptococcus. Infection 2003;31:244-246.
38. Aracil B, Minambres M, Oteo J, De La Rosa M, Gomez-Garces JL, Alos AJ: Susceptibility of strains of Streptococcus agalactiae to macrolides and lincosamides, phenotype patterns and resistance genes. Clin Microbiol Infect 2002;8:745-748.
39. Alhambra A, Gomez-Garces JL, Alos JI: Susceptibility of Streptococcus agalactiae isolates from blood and urine to 18 widely used and recently marketed antibiotics. Clin Microbiol Infect 2004;10:267-268.
40. Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL: Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001;108:1094-1098.
41. Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, Schuchat A: Trends in incidence and antimicrobial resistance of early-onset sepsis: Population-based surveillance in San Francisco and Atlanta. Pediatrics 2002;110:690-695.
42. Fourmaux S, Bebear C: Urogenital infections linked to Chlamydia and mycoplasmas. Prog Urol 1997;7:132-136.
43. Arya OP, Tong CY, Hart CA, et al: Is Mycoplasma hominis a vaginal pathogen? Sex Transm Infect 2001;77:58-62.
44. Jensen JS: Mycoplasma genitalium: The aetiological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol 2004;18:1-11.
45. Peipert JF: Clinical practice: Genital chlamydial infections. N Engl J Med 2003;349:2424-2430.
46. Skapinyecz J, Smid I, Juhasz A, Jeney C, Rozgonyi F, Kovacs P: Planning of empirical antibiotic therapy for women with pelvic inflammatory diseases: A geographical area-specific study. Eur J Obstet Gynecol Reprod Biol 2003;111:183-188.
47. Pereyre S, Gonzalez P, De Barbeyrac B, et al: Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob Agents Chemother 2002;46:3142-3150.
48. Taylor-Robinson D, Bebear C: Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J Antimicrob Chemother 1997;40:622-630.
49. Koutsky LA, Stamm WE, Brunham RC, et al: Persistence of Mycoplasma hominis after therapy: Importance of tetracycline resistance and of coexisting vaginal flora. Sex Transm Dis 1983;10(suppl):374-381.
50. Cummings MC, McCormack WM: Increase in resistance of Mycoplasma hominis to tetracyclines. Antimicrob Agents Chemother 1990;34:2297-2299.
51. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001;45:2604-2608.
52. Ullmann U, Schubert S, Krausse R: Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999;43(suppl C):33-36.
53. Domingues D, Tavora Tavira L, Duarte A, Sanca A, Prieto E, Exposto F: Genital mycoplasmas in women attending a family planning clinic in Guine-Bissau and their susceptibility to antimicrobial agents. Acta Trop 2003;86:19-24.
54. Ngan CC, Lim T, Choo CM, Toh GL, Lim YS: Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method. Diagn Microbiol Infect Dis 2004;48:207-210.
55. Waites KB, Canupp KC, Kenny GE: In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test. Antimicrob Agents Chemother 1999;43:2571-2573.
56. Samra Z, Rosenberg S, Soffer Y: In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides. Diagn Microbiol Infect Dis 2002;44:359-361.
57. Bebear CM, Renaudin J, Charron A, et al: Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother 1999;43:954-956.
58. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrançois M, Bebear C: In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized. Antimicrob Agents Chemother 2000;44:2557-2560.
59. Kilic D, Basar MM, Kaygusuz S, Yilmaz E, Basar H, Batislam E: Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis. Jpn J Infect Dis 2004;57:17-20.
60. Cakan H, Polat E, Kocazeybek B, et al: Assessment of antibiotic susceptibility of Ureaplasma urealyticum from prostitutes and outpatient clinic patients using the E-test and agar dilution method. Chemotherapy 2003;49:39-43.
61. Taylor-Robinson D, Furr PM: Clinical antibiotic resistance of Ureaplasma urealyticum. Pediatr Infect Dis 1986;5(suppl):S335-337.
62. Eschenbach DA, Nugent RP, Rao AV, et al: A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery: The Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1991;164:734-742.
63. Smelov V, Krylova T, Smelova N, Norman L: Azithromycin treatment follow-up: Antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis. Int J Antimicrob Agents 2004;23(suppl 1):S79-82.
64. Samra Z, Rosenberg S, Soffer Y, Dan M: In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001;39:177-179.
65. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS: Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995;39:760-762.
66. Lefevre JC, Lepargneur JP, Guion D, Bei S: Tetracycline-resistant Chlamydia trachomatis in Toulouse, France. Pathol Biol (Paris) 1997;45:376-378.
67. Jones RB, Van der Pol B, Martin DH, Shepard MK: Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990;162:1309-1315.
68. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM: Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000;181:1421-1427.